Cirrhotic cardiomyopathy: a subject that's always topical

References

• Izzy M, VanWagner LB, Lin G et al. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 71, 334–345 (2020).
   PubMed Web of Science ®Google Scholar
• Marchetta S, Delwaide J, Lancellotti R. La cardiomyopathie du cirrhotique: un bref aperçu. Rev. Med. Liege. 70(2), 86–91 (2015).
   PubMedGoogle Scholar
• Zard EM, Abbate A, Zardi DM et al. Cirrhotic Cardiomyopathy. J. Am. Coll. Cardiol. 56, 539–549 (2010).
   PubMed Web of Science ®Google Scholar
• Enache I, Oswald-Mammosser M, Woehl-Jaegle MLb et al. Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir. Med. 107(7), 1030–1036 (2013).
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 57(2), 268–278 (2008).
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Pellikka PA, Budts W et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 30, 101–138 (2017).
   PubMed Web of Science ®Google Scholar
• Marwick TH, Gillebert TC, Aurigemma G et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J. Am. Soc. Echocardiogr. 28, 727–754 (2015).
   PubMed Web of Science ®Google Scholar
• Ternacle J, Berry M, Alonso E et al. Incremental value of global longitudinal strain for predicting early outcome after cardiac surgery. Eur. Heart. J. Cardiovasc. Imaging. 14, 77–84 (2013).
   PubMed Web of Science ®Google Scholar
• Sjoli B, Grenne B, Smiseth OA, Edvardsen T, Brunvand H. The advantage of global strain compared to left ventricular ejection fraction to predict outcome after acute myocardial infarction. Echocardiography. 28, 556–563 (2011).
   PubMed Web of Science ®Google Scholar
• Lauridsen TK, Alhede C, Crowley AL et al. Two-dimensional global longitudinal strain is superior to left ventricular ejection fraction in prediction of outcome in patients with left-sided infective endocarditis. Int. J. Cardiol. 260, 118–123 (2018).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–e239 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng S, Larson MG, McCabe EL et al. Age and sex-based reference limits and clinical correlates of myocardial strain and synchrony: the Framingham Heart Study. Circ Cardiovasc. Imaging. 6, 692–699 (2013).
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28, 233–270 (2015).
   Web of Science ®Google Scholar
• Chen Y, Chan AC, Chan SC et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J. Cardiol. 67, 140–146 (2016).
   PubMed Web of Science ®Google Scholar
• Sampaio F, Pimenta J, Bettencourt N et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver. Int. 33, 1158–1165 (2013).
   PubMed Web of Science ®Google Scholar
• Hammami R, Boudabbous M, Jdidi J et al. Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease? Libyan. J. Med. 12(1), 1283162 (2017).
   PubMedGoogle Scholar
• Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World. J. Gastroenterol. 20(42), 15499–15517 (2014).
   PubMed Web of Science ®Google Scholar
• Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med. 119(7), 47–53 (2006).
   PubMedGoogle Scholar
• Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42(2), 439–447 (2005).
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59, 105–110 (2010).
   PubMed Web of Science ®Google Scholar
• Krag A, Møller S, Burroughs AK, Bendtsen F. Betablockers induce cardiac chronotropic incompetence. J. Hepatol. 56, 298–299 (2012).
   PubMed Web of Science ®Google Scholar
• Bernardi M, Calandra S, Colantoni A et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27(1), 28–33 (1998).
   PubMed Web of Science ®Google Scholar
• Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver. Int. 23(4), 243–248 (2003).
   PubMed Web of Science ®Google Scholar
• Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological ab normalities in patients with cirrhosis. J. Hepatol. 44(5), 994–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Trevisani F, Di Micoli A, Zambruni A et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver. Int. 32(10), 1510–1515 (2012).
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J. Hepatol. 40(2), 239–246 (2004).
   PubMed Web of Science ®Google Scholar
• Zambruni A, Trevisani F, Di Micoli A et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J. Hepatol. 48(3), 415–421 (2008).
   PubMed Web of Science ®Google Scholar
• Serste T, Melot C, Francoz C et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52(3), 1017–1022 (2010).
   PubMed Web of Science ®Google Scholar
• Serste T, Francoz C, Durand F et al. Betablockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J. Hepatol. 55(4), 794–799 (2011).
   PubMed Web of Science ®Google Scholar
• Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert. Rev. Gastroenterol. Hepatol 6(1), 57–66 (2012).
   Web of Science ®Google Scholar
• Bernardi M, Rubboli A, Trevisani F et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J. Hepatol. 12(2), 207–216 (1991).
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J. Hepatol. 36(4), 513–520 (2002).
   PubMed Web of Science ®Google Scholar
• Ortiz-Olvera NX, Castellanos-Pallares G, Gomez-Jimenez LM et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann. Hepatol. 10(3), 321–326 (2011).
   PubMed Web of Science ®Google Scholar
• Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat. Rev. Gastroenterol. Hepatol 11(3), 177–86 (2014).
   PubMed Web of Science ®Google Scholar
• Dourakis SP, Geladari E, Geladari C, Vallianou N. Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased? Curr. Cardiol. Rev. 17(1), 78–84 (2021).
   PubMed Web of Science ®Google Scholar
• Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol. Int. 8(3), 308–315 (2014).
   PubMed Web of Science ®Google Scholar
• Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 52(3), 811–813 (2010).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J. 85(999), 44–54 (2009).
   PubMed Web of Science ®Google Scholar
• Jia G, Aroor AR, Hill MA, Sowers JR. Role of RAAS activation in promoting cardiovascular fibrosis and stiffness. Hypertension 72(3), 537–548 (2018).
   PubMed Web of Science ®Google Scholar
• Saner FH, Neumann T, Canbay A et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl. Int. 24(5), 425–432 (2011).
   PubMed Web of Science ®Google Scholar
• Torregrosa M, Aguadé S, Dos L et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J. Hepatol. 42(1), 68–74 (2005).
   PubMed Web of Science ®Google Scholar